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Abstract
Background: Malawi commenced the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) into the
routine infant immunisation schedule in November 2011. Here we have tested the utility of high throughput whole genome
sequencing to provide a high-resolution view of pre-vaccine pneumococcal epidemiology and population evolutionary
trends to predict potential future change in population structure post introduction.
Methods: One hundred and twenty seven (127) archived pneumococcal isolates from randomly selected adults and children
presenting to the Queen Elizabeth Central Hospital, Blantyre, Malawi underwent whole genome sequencing.
Results: The pneumococcal population was dominated by serotype 1 (20.5% of invasive isolates) prior to vaccine
introduction. PCV13 is likely to protect against 62.9% of all circulating invasive pneumococci (78.3% in under-5-year-olds).
Several Pneumococcal Molecular Epidemiology Network (PMEN) clones are now in circulation in Malawi which were
previously undetected but the pandemic multidrug resistant PMEN1 lineage was not identified. Genome analysis identified
a number of novel sequence types and serotype switching.
Conclusions: High throughput genome sequencing is now feasible and has the capacity to simultaneously elucidate
serotype, sequence type and as well as detailed genetic information. It enables population level characterization, providing
a detailed picture of population structure and genome evolution relevant to disease control. Post-vaccine introduction
surveillance supported by genome sequencing is essential to providing a comprehensive picture of the impact of PCV13 on
pneumococcal population structure and informing future public health interventions.
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Introduction
Approximately 1.1 million deaths annually are attributed to
invasive pneumococcal disease (IPD) worldwide, accounting for
9% of all deaths in developing countries [1] In Malawi the
pneumococcus is a leading cause of pneumonia, bacteraemia and
meningitis in both children and adults, and consequently a
prominent cause of death [2,3,4]. Vaccine prevention of
pneumococcal disease is therefore a public health priority.
Routine pneumococcal vaccination with PCV13 was introduced
as part of the infant expanded programme of immunization in
November 2011. Pneumococcal vaccine was not licensed or
routinely available before this introduction. The vaccine pro-
gramme is expected to be highly successful but based on
experience in Europe and the United States, rapid epidemiological
change is likely to follow vaccine introduction [5]. We have
previously described 10 years of clinical phenotypic surveillance of
pneumococcal invasive disease, which detailed a persistent decline
in admissions with IPD to a large district and tertiary referral
hospital in Blantyre, Malawi [6]. We have highlighted that
pneumococcal epidemiology in Malawi is undergoing change
prior to the introduction of vaccine.
Understanding this change in epidemiology requires reproduc-
ible and robust molecular typing methods. A range of techniques
have been used, these include serotyping, antimicrobial resistance
phenotyping and multilocus sequence typing (MLST)
[7,8,9,10,11,12,13]. However, because of the highly diverse and
recombinogenic nature of the pneumococcus, these approaches
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may not provide sufficient resolution and adequately predict
change over time in complex populations. Whole genome
sequencing is rapidly becoming an economically viable option
for genetic analysis of large collections of bacterial isolates
representing natural populations [14,15,16] giving unprecedented
resolution on the individual genetics and relationships between
strains. To provide a preliminary picture of invasive pneumococcal
populations in Malawi and inform post-introduction surveillance
of pneumococcal disease, we have therefore characterised a
sample of 127 invasive pneumococcal isolates from 2003–2008
using high throughput whole genome sequencing.
Results
Whole genome assemblies were generated for all 127 isolates
and the protein sequences of 388 shared orthologous genes
extracted and aligned to create the phylogenetic tree represented
in Figure 1. Within the tree there are several clusters of similar
sequence, which can be correlated with other characterizing
metrics such as serotype and drug resistance profile. It is also
notable that even for very closely related isolates within clusters it
is possible, using the whole genome data, to specifically distinguish
every isolate. Multi-locus sequence type (MLST) was derived from
the sequence data to allow comparison of the genetic diversity of
this sample with other samples in the literature and the entire
public MLST database.
Serotype Distribution and Pneumococcal Conjugate
Vaccine Coverage
The serotype of each isolate was determined by mapping
Illumina reads against a reference of concatenated capsular
biosynthesis loci (cps) for all known serotypes (Figure 1). There
were thirty-nine (39) circulating serotypes amongst the isolates: 22
were found in invasive isolates only, 1 from carriage only (15A)
and 14 from both invasive disease and carriage. Six isolates (3, 5,
7F, 18C, 19A, 23F) were only associated with invasive disease and
had population frequencies of greater than 3, but all are included
in PCV13. Serotypes 13, 21 and 35B were more frequent in
carriage than invasive disease. There were no non-typeable
isolates amongst the carriage group. There were clusters though
of serotypes 1, 3, 5, 6A/B, 7A/F, 10B, 12A/B, 14 and 23F
correlating with genotypes previously reported [17].
Figure 2 details the cumulative distribution of serotypes detected
directly from the genome in this study. The most common invasive
serotypes in our selection were serotypes 1 (20.5%), 5 (6.3%), 6A
(5.5%), 14 (5.5%), 12B (4.7%), 23F (3.9%) and 19F (3.1%),
accounting for 49.5% of the serotypes detected within the
population. Our data suggests that the 13-valent pneumococcal
conjugate vaccine (PCV13) would provide 62.9% (95% CI 54.5 -
71.3%) coverage against all IPD in Malawi. However the vaccine
is scheduled for children under-5 years old. 43.4% (46/106) of
invasive isolates were from this age group and PCV13 coverage
would be 78.3% (36/46).
Antibiotic Resistance
If we remove the PCV13 serotypes from the analysis, 22.9% (8/
35) of non-vaccine serotypes would be classified as multidrug
resistant (MDR) by being resistant to at least 3 classes of antibiotics
(File S1) and 25.7% (9/35) would be resistant to at least 2 classes of
antibiotic. Drug resistance is clustered within the 10B, 12B and
16F carried and invasive groups on the tree (Figure 1).
Sequence Type
The population diversity as judged by ST comprised of 20
distinct clonal groups. Novel STs accounted for 29.9% (38/127) of
the population and included novel STs derived for serotypes 6B,
7F, 13, 18A and 19A (Table 1).
The Pneumococcal Molecular Epidemiology Network (PMEN)
27 clone (Sequence Type [ST] 217) was exclusively associated with
serotype 1 and PMEN 19 (ST289) with serotype 5 (Table 1). The
23F cluster corresponded to ST802; for two isolates within that
cluster we could not assemble complete MLST genes but the
whole genome data allows us to confidently place them within the
ST802 group. Similarly one 12B sits within the ST989 group and
a single 16F sits within the ST705 group (Figure 1). Two novel ST,
serotype 12B isolates, cluster together, but not with the larger
ST989 grouping. The serotype 14 cluster was predominately ST63
(75%), with a single ST2678 and a single novel ST. ST63
represents the PMEN 25 clone, which is known to express serotype
15A. However only serotypes 15B and 15C were identified of the
serotype 15 cluster. The cluster of serotype 10B isolates did not
correspond to a known MLST, but three of this cluster were from
invasive serotypes and accounted for 2.4% of the population. No
members of the pandemic 23F clone first identified in Spain
(PMEN1, 23F-Spain, ST81) were detected [18,19,20].
Lineage-serotype Associations
Figure 3 provides an overall summary of the genomic diversity
associated with the serotypes targeted by the PCV13; Serotypes 1,
5 and 23F were exclusively detected from single lineages (distance
of isolates falling within 0–0.002 amino acid changes per site),
while some serotypes were detected from multiple lineages
(distance .0.002 amino acid substitution per site). The vaccine
will target more than one lineage associated with 3 serotypes (6A,
14 and 19F), which will potentially have different propensities to
cause disease or association with antibiotic resistance. Lineage-
serotype associations allow for the potential detection of serotype
switch events; within this sample we found two isolates with the
same ST (ST172) but unrelated serotypes (19F and 15C)
indicating a likely serotype change within this lineage due to
exchange of the cps locus via recombination. However, the
genomic distance indicated by the branch lengths shows that these
isolates are not as closely related as may be assumed by the
common MLST type suggesting that the serotype switch is not a
recent event and that there are likely to be many further genetic
differences between these isolates. The serogroup 7 cluster appears
to indicate a more recent switch event from serotype 7F to 7A.
The difference between these serotypes is subtle, due to a single
base insertion/deletion causing a frameshift in a glycosyl
transferase gene thus altering the sugar composition of the
repeating unit (PMID: 17766424). Our current assemblies of this
specific location are not conclusive so further confirmation is
required, nevertheless, the subtlety of the variation suggests that
7A/7F switches will be relatively frequent in nature.
Carriage
There were 17 serotypes identified within this group and only 3
serotypes (6A, 7F and 19F) from 4 isolates (4/21, 19.1%) were
included in the PCV13. Seven STs were identified, 7 were
designated novel and 7 were incomplete and unable to determine.
A single PMEN 25 (ST63) clone expressing serotype 14 was
identified in this group. Carriage isolates were evenly distributed
throughout the tree with no apparent clustering.
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Discussion
Until recently serotyping, antimicrobial resistance phenotyping
and MLST have formed the basis for describing pneumococcal
populations. Here we show that high throughput sequencing
provides a comprehensive description of invasive pneumococci in
Malawi through a single technique.
Serotype Distribution
Deriving serotype from the genome data has allowed us to
accurately define a serotype and serotype distribution of circulat-
ing strains in Malawi and predict the coverage of the conjugate
vaccine (Figure 2). In total thirty-nine circulating serotypes were
detected which is consistent with other African reports [21,22].
Amongst the invasive pneumococcal isolates, serotype 1 predom-
Figure 1. Phlyogenetic tree of Malawian strains.
doi:10.1371/journal.pone.0044250.g001
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inated the circulating population with 20.5% of all invasive isolates
attributable to this serotype. Serotype 5 (6.3%) was the next most
commonly encountered invasive serotypes in our population. The
dominance of serotype 1 and 5 has not changed in our setting over
time, although the distribution across the population has reduced
[23]. With the exception of 12B all the dominant serotypes
observed in this study are included in the in PCV13. As the impact
of the vaccine becomes more apparent and widespread it will
therefore be essential to monitor the prevalence of 12B amongst
invasive pneumococcal isolates. Across Africa, serotypes 1, 5 and
14 have also been commonly reported as major invasive serotypes
[24]. In Europe the most common invasive serotypes have been
reported as 6B, 14, 19F and 23F (quite different from the common
Malawian serotypes) [25], however taking these data together it
appears that the breadth of the PCV13 is currently sufficient to
substantially prevent IPD (outside of the original target popula-
tions of North America and Europe) [24,25].
Nonetheless our data suggests that PCV13 would prevent
62.9% of all IPD cases and 78.3% of cases in under 5 year olds in
Malawi. This was not unexpected because coverage concerns in
our setting have been previously reported [23]. This compares
with almost 90% prior to the vaccine roll out in The United States
[26,27]. The coverage amongst Malawian isolates is conditional
on a strong protective effect against serotype 1. Previous
formulations have provided uncertain protection against this
important serotype [28]. Without serotype 1 efficacy PCV13
coverage in Malawi could be as low as 42.4%. These differences
highlight the need for broadening the vaccines coverage to include
serotypes in circulation within SSA either by increasing the
valency by the development of protein based vaccines or through a
combination of the two [29]. The results of this study have led us
to undertake a much broader prospective carriage study to collect
more data on a much larger collection of isolates as the impact of
vaccination increases in the coming years.
Antibiotic Resistance and Vaccine Serotypes
22.9% (8/35) of non-vaccine serotypes were multidrug resistant
(MDR) and 25.7% (9/35) were resistant to at least 2 classes of
antibiotic (as determined by conventional disc testing - File S1). All
serotype 12B isolates were resistant to at least 2 classes of
antibiotics, 50% of these were MDR. The introduction of PCV13
therefore may drive the emergence of antibiotic resistant 12B and
other MDR non-vaccine serotypes, such as 16F and warrants
monitoring over the coming years.
Sequence Type
By deriving the STs genomically we were able to assign 89/
127 (70.1%) isolates to 20 known STs (Table 1). Of note, 38/
127 (30%) isolates were assigned to novel STs. By analysing
whole genome phylogeny, we are able to confidently predict
that 15.8% (6/38) of our novel STs will be situated within
known clonal groups. Based on these predictions, we estimate
that 84.2% (32/38) of the novel STs defined by the MLST
website are truly novel. This clearly demonstrates the huge
genetic diversity amongst the circulating Malawian invasive
pneumococcal population. Of the known STs, unsurprisingly
ST217 (all serotype 1) is the predominant ST in circulation,
accounting for 18.9% (24/127) of the total.
We identified three clones amongst the Malawian isolates
previously identified as PMEN clones 19 (ST289), 25 (ST63) and
27 (ST217), as having a wide geographic distribution (Table 1 and
www.sph.emory.edu/PMEN). These clones appear established in
Malawi given their frequency across the entire sampling period
Figure 2. Bar chart showing rank order and cumulative serotype distribution (%).
doi:10.1371/journal.pone.0044250.g002
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(2003–2008, File S1). No members of the pandemic Spanish 23F
clone (PMEN1, 23F-Spain, ST81) were detected.
MLST is an excellent tool, but can be heavily biased because of
the tendency to focus on the dominant lineages in typing studies
and therefore these are the lineages that are submitted [17].
Routine whole genome sequencing has the potential to be less
biased as evidenced by the increased proportion of novel STs
identified in this population and the ability to place unknown STs
within particular serotype and ST groupings. In addition, analysis
of the MLST genes can be used to determine ST thus allowing
comparison with previously collected genotypic data described in
the MLST database and in the literature. Analysis of the MLST
database (www.mlst.net) showed similarities across the STs of the
predominant Malawian serotypes and West Africa, but not to its
nearest neighbours (Mozambique, Kenya or South Africa). This
emphasizes the need to routinely deposit all isolates from routine
surveillance in order to maximize the utility of this resource.
Genotype
Genotypic analysis revealed a large degree of genetic hetero-
geneity within our population. To highlight future application of
the vaccine in 2011, serotypes targeted by PCV13 were shaded in
grey in Figure 1. Here, a serotype switch and a replacement of
non-vaccine type may be predictable. An example highlighted in
red is a cluster of unknown lineage associated with a carriage, a
pneumonia and bacteraemic cases. Vaccine implementation
would remove all 7F but leave bacteraemia-associated 7A of the
same lineage. A similar scenario could occur with other serotypes.
These techniques provide a unique opportunity to understand the
pressures vaccine introduction will place on the pneumococcus
and provide insights, which will inform this and future interven-
tions.
Figure 3 illustrates that some serotypes were exclusively detected
from single lineages, while some serotypes were detected from
multiple lineages. Serotypes distributed within single lineages
include 1 and 5 (left and middle diagrams in middle panel), which
are exclusively associated with ST217 and ST289 respectively.
Serotype 23F, slightly right shifted, were carried by ST802 and
new STs. However, serotypes 14, 6A and 19F were detected in
more than one lineage as shown by a right shift towards higher
diversity in phylogenetic tree (bottom panel).
Following the introduction of PCV7 pneumococcal population
structure within many countries changed by removing previously
dominant clones. Methods of escape ensued resulting in serotype
switching for example. In our current invasive population by
employing the genome sequence data to derive phylogenetic
relationships predict serotype and visualize lineage-serotype
associations, we identified isolates with the same ST (ST172) but
unrelated serotypes (19F and 15C). Thus indicating a likely
serotype change within this lineage due to exchange of the cps
locus via a recombination and also demonstrated the potential to
detect more subtle serotype switches. Based on the clustering on
the phylogenetic tree (Figure 1) predict that following full and
stable coverage of PCV13, isolates expressing serotype 7A could
switch to 7F, 19Fs could switch to 15C and serotypes 10B, 12B
and 16F could emerge as major invasive drug resistant serotypes.
Figure 3. Genomic diversity of serotypes targeted by PCV13.
doi:10.1371/journal.pone.0044250.g003
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Summary
Pneumococcal infections place a high social, health and
economic burden on the infrastructure of resource-poor countries
[30]. Whole genome sequencing provides a precise measure of
population change over time, which was previously difficult and
time consuming to achieve. It provides a greater population
resolution than individually derived data extraction methods and a
means to not only describe the pneumococcal population with
unprecedented genetic detail, but it also provided the means to
accurately detect and predict important changes within circulating
clonal complexes, serotype distribution and serotype switches as
the vaccine is implemented.
Methods
Ethics
The anonymised isolates characterised in this study are all
clinical isolates from specimens obtained from Malawian adults
and children as part of routine clinical diagnosis and management
when they were admitted to QECH. The main ethical issue relates
to specific consent for detailed characterisation of an isolate from a
clinical specimen taken from a patient on clinical grounds. This
requirement was waived by the University of Malawi, College of
Medicine Research & Ethics Committee because the characterisa-
tion formed part of routine clinical management. The data are
therefore published with the approval of the Research & Ethics
Committee and conform to institutional guidelines.
Setting
Queen Elizabeth Central Hospital (QECH) is a 1250 bed
government-funded hospital, serving a population of ,1 million,
including the city of Blantyre, the surrounding townships, and
outlying villages.
Pneumococcal Isolate Selection
Isolation methodology and sensitivity testing protocols has been
previously described [6]. Antimicrobial resistance but not
serotyping was routinely performed on all isolates. The Malawi-
Liverpool-Wellcome Trust Clinical Research Programme (MLW)
has archived over 5000 carried and invasive pneumococcal isolates
since 1996. One hundred and thirty-four invasive and carried
isolates (134, 4.2%) were randomly selected (age range 1 day to
63 yrs) within individual years between 2003–2008 from a total of
3179 available isolates for this study. The rationale for the number
is derived from the number of sequencing lanes we were offered by
WTSI for the sequencing pilot (19 lanes, each lane had a capacity
for 7 isolates = 133). An additional isolate as sent in error, which
was subsequently sequenced and included.
However data is only available for 127 strains (106 invasive and
21 carriage) due to either insufficient quality of DNA or final
sequence reads. The selection comprised of adult and paediatric
bacteraemic and meningitis isolates. The number of carried
isolates corresponded to 10% of those available within the time
frame. The remainder (134-21= 113) were allocated to the
invasive group. In total 4.6% of all isolates available in that
specified time frame were sequenced.
Bacterial Culture and Genomic DNA Preparation
Liquid medium (Todd-Hewitt broth) was inoculated and grown
overnight at 37uC. Genomic DNA preparation was performed
using the Promega Wizard Genomic DNA Purification Kit
(Promega, USA, Product Number A1125) A minimum of 50 ml
of extracted DNA with a concentration 20 ng/ml and in a volume
of 100 ml, and in fragments .10 kb was shipped for sequencing.
Whole Genome Sequencing and Sequence Analysis
Sequencing: Index tagged libraries for each S. pneumoniae isolate
were prepared, pooled and sequenced on the Illumina Genome
Analyzer GAII as described previously [14]. Short reads were
assembled using Velvet v1.0.03 [31], and ordered relative to a
complete reference genome sequence (Accession number:
FM211187) [32] using Abacus v2.5.1 [33].
Read mapping: Illumina sequence data as paired end reads with
an insert size between 50 and 400 bp were mapped onto the
reference genome S. pneumoniae ATCC 700669 (Accession number:
FM211187) using SSAHA v2.2.1 [34], giving on average, 23x
depth of coverage and more than 79.4% coverage of the reference
genome.
Serotype and Sequence type: Serotype and MLST type were
derived as described previously by Croucher et al [14].
Phylogenetic Analysis
A phylogenetic tree of 127 pneumococcal genomes was created
using RAxML v.7.2.8 [35] as described in Harris et al [15,36], for
all sites in the nucleotide sequences containing SNPs, using
GAMMA correction and five starting trees. One-hundred (100)
bootstraps were generated to validate the tree, which represents
the best overall estimate of evolutionary history from our data.
Pair-wise distance between samples within a tree was used as a
tool to investigate diversity within vaccine serotypes. We used R
version 2.11.1 [37] to plot population density based on sample
pair-wise distance for each serotype.
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